Neurocrine Biosciences, Inc. $NBIX Shares Purchased by National Pension Service

National Pension Service boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 184.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 28,305 shares of the company’s stock after purchasing an additional 18,354 shares during the period. National Pension Service’s holdings in Neurocrine Biosciences were worth $4,014,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. USA Financial Formulas acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $25,000. Geneos Wealth Management Inc. grew its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Neurocrine Biosciences in the third quarter worth $49,000. Leonteq Securities AG acquired a new position in shares of Neurocrine Biosciences in the fourth quarter worth $58,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Neurocrine Biosciences by 112.0% in the third quarter. Smartleaf Asset Management LLC now owns 424 shares of the company’s stock worth $59,000 after acquiring an additional 224 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In related news, Director Leslie V. Norwalk sold 3,810 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $155.01, for a total transaction of $590,588.10. Following the completion of the transaction, the director owned 2,429 shares in the company, valued at approximately $376,519.29. The trade was a 61.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This trade represents a 30.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 278,786 shares of company stock valued at $43,099,615. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several research reports. Guggenheim restated a “buy” rating and issued a $175.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 21st. HC Wainwright boosted their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Wells Fargo & Company dropped their price target on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Finally, Canaccord Genuity Group boosted their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average price target of $186.05.

Neurocrine Biosciences Trading Up 1.7%

Shares of NBIX stock opened at $161.00 on Tuesday. The firm has a fifty day moving average price of $139.98 and a 200 day moving average price of $139.18. The company has a market cap of $16.19 billion, a P/E ratio of 24.81, a PEG ratio of 1.19 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12 month low of $121.83 and a 12 month high of $162.39.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.